TIGHT JUNCTION MODULATOR PEPTIDES FOR ENHANCED MUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS
First Claim
Patent Images
1. An isolated peptide comprising a sequence selected from the group consisting of SEQ ID NOs:
- 1 and 20-23 lengthened by one or more amino acid residues, and pharmaceutically-acceptable salts thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
Compositions and methods are provided that include a biologically active agent and a permeabilizing agent effective to enhance mucosal delivery of the biologically active agent in a mammalian subject, in which the permeabilizing peptide is a PN159 analog or conjugate.
-
Citations
21 Claims
-
1. An isolated peptide comprising a sequence selected from the group consisting of SEQ ID NOs:
- 1 and 20-23 lengthened by one or more amino acid residues, and pharmaceutically-acceptable salts thereof.
- View Dependent Claims (2, 3, 4, 5)
-
6. An isolated peptide comprising a sequence selected from the group consisting of
SEQ ID NOs: - 1 and 20-23, and variants thereof, having 14-26 amino acid residues, wherein the peptide has at least two D-amino acid residues, and pharmaceutically-acceptable salts thereof.
- View Dependent Claims (7, 8, 9, 10)
-
11. An isolated peptide comprising the retro-inverso of a sequence selected from the group consisting of SEQ ID NOs:
- 1 and 20-23, and variants thereof, having 14-26 amino acid residues, and pharmaceutically-acceptable salts thereof.
- View Dependent Claims (12, 13, 14, 15)
-
16. An isolated peptide comprising a sequence selected from the group consisting of
SEQ ID NOs: - 1 and 20-23, and variants thereof, having 14-26 amino acid residues, wherein the peptide is enriched with at least 60% lysine, leucine, and/or alanine, and pharmaceutically-acceptable salts thereof.
- View Dependent Claims (17, 18, 19, 20, 21)
Specification